ArticleVeterinary research communications2026
Cinnabarinic acid regulates the barrier function and inflammatory reactions in primary chicken intestinal epithelial cells with hyperthermia treatment via the aryl hydrocarbon receptor.
Article in Veterinary research communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
This study aimed to evaluate the efficacy of cinnabarinic acid (CA) in regulating the barrier function and inflammatory responses of primary intestinal epithelial cells (IECs) derived from chicken embryos subjected to hyperthermia, so as to provide a theoretical basis for alleviating heat stress in broilers. The IECs were randomly divided into 4 groups, a thermoneutral group (37 °C), a hyperthermia group (43 °C), a hyperthermia + CA group and a hyperthermia + CA + aryl hydrocarbon receptor (AhR) inhibitor group. A hyperthermia cell model was established by exposing IECs to 43 °C for 6 h, and the experimental treatments consisted of 1 µmol/L CA and 1 µmol/L AhR inhibitor. According to the results, the supplementation of 1 µmol/L CA into the basal culture medium markedly improved the relative cell viability of hyperthermia-treated IECs, decreased the levels of lactate dehydrogenase (LDH), tumor necrosis factor alpha (TNF-α), and interleukin (IL)-1β in cell culture supernatants, downregulated the mRNA expression of heat shock protein (HSP)70, HSP90, claudin2, toll-like receptor (TLR)4, TLR5 and TLR21, increased AhR protein expression and the mRNA expression of occludin, increased the secretion of IL-22 of IECs treated with hyperthermia. Notably, the protective and regulatory effects of CA were markedly abolished by the AhR inhibitor under hyperthermic conditions. In conclusion, CA activated AhR in IECs, promoted IL-22 secretion, inhibited inflammatory responses, increased tight junction proteins genes expression, enhanced epithelial barrier integrity.
Indexed as
Identifiers
42258090What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.